docetaxel + oxaliplatin (Ulm University)

docetaxel + oxaliplatin (DocOx) is a combination chemotherapy regimen investigated as a second-line treatment for advanced or metastatic pancreatic adenocarcinoma. Developed through a Phase II clinical trial (AIO-PK0106) led by the University of Ulm, the regimen involves the sequential administration of docetaxel, a taxane that stabilizes microtubules to inhibit mitotic division, and oxaliplatin, a platinum-based antineoplastic agent that forms DNA crosslinks to trigger apoptosis. The trial specifically targeted patients who had failed first-line gemcitabine-based therapy, demonstrating clinical activity in this refractory population. The regimen is typically administered in 21-day cycles, with docetaxel given on day 1 and oxaliplatin on day 2.

Other names

DocOxDocOx regimendocetaxel and oxaliplatin